[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

August 2017 | 29 pages | ID: CCB63ADD72CEN
La Merie Publishing

US$ 350.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This Competitive Intelligence report about Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017 provides a competitor evaluation in the field of antibodies, vaccines and engineered chimeric antigen receptor (CAR) T-cells targeting mesothelin as of August 2017.

Mesothelin is a surface marker protein overexpressed in many cancers and is a suitable target for directing immunotherapeutics to mesothelin expressing tumors, such as malignant pleural mesothelioma, mesothelioma and pancreatic, non-small cell lung, ovarian, endometrial and gastric cancers.

The report includes a compilation of currently active projects in research and development of antibodies, vaccines and engineered T-cells directed against mesothelin. In addition, the report lists company- and institution-specific R&D pipelines of anti-Mesothelin Immunotherapeutics. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017
  • Mesothelin-Targeted Antibodies
  • Mesothelin-Targeted Vaccines
  • Mesothelin-Targeted Engineered CAR T-Cells
2) Corporate & Institutional Anti-Mesothelin R&D Pipelines


More Publications